ibuprofen-arginine and Chronic-Disease

The aim of this controlled clinical trial was to investigate the analgesic efficacy and tolerability of ibuprofen arginine in patients with mild-to-moderate periodontitis during and after non-surgical periodontal treatment.. This randomized, triple-blind, placebo-controlled, parallel-group trial assessed the analgesic efficacy of ibuprofen arginine (Spedifen) in patients undergoing routine periodontal scaling and root planing. 64 patients with chronic periodontitis received either 800 mg ibuprofen arginine or placebo 30 min. before treatment. Numeric pain and electronic visual analogue scales ranging from 0 to 100 were used.. The average pain levels during treatment were lower following ibuprofen arginine (quartiles: 0.5, 4.5, 11) compared with placebo (4, 16, 26), corresponding to a percentage reduction in median pain of 72% (p=0.023). The median maximum pain was 28 (inter-quartile range 10-50) following placebo and 10 (4-31) following ibuprofen arginine (p=0.065).. In patients with mild-to-moderate chronic periodontitis, ibuprofen arginine was safe and superior to placebo for alleviating pain during non-surgical periodontal treatment. Its painless administration and rapid onset of action make it well suitable for pain management in a general dental office.

Topics: Adult; Aged; Analgesics, Non-Narcotic; Arginine; Chronic Disease; Dental Scaling; Double-Blind Method; Drug Combinations; Female; Humans; Ibuprofen; Male; Middle Aged; Pain Measurement; Periodontitis; Root Planing; Statistics, Nonparametric; Toothache

To determine whether ibuprofen-arginine has a cyclooxygenase-independent pain modulating property in addition to its known antiinflammatory effect.. Patients with chronic low back pain were randomly divided into 2 groups treated either with oral ibuprofen-arginine (400 mg) or with placebo. Blood was drawn from study subjects before, during, and after treatment and they were asked each time about the intensity of their pain. Concentrations of nitric oxide (NO) metabolites were determined.. Twenty minutes after intake of ibuprofen-arginine, but not after placebo, there was a relevant and significant reduction of NO metabolites in serum. In both groups there was significant analgesic effect compared to baseline.. An early lowering of the serum NO metabolite levels after ibuprofen-arginine administration could be detected in patients with chronic low back pain.

Topics: Analgesics; Arginine; Chronic Disease; Drug Combinations; Female; Humans; Ibuprofen; Low Back Pain; Male; Middle Aged; Nitric Oxide; Pain Measurement; Pilot Projects; Single-Blind Method; Treatment Outcome